2
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Terminated
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gastrointestinal
1
Conditions
Carcinoma, Renal Cell
145
Kidney Neoplasms
42
Neoplasms
39
Neoplasm Metastasis
35
Breast Neoplasms
33
Gastrointestinal Stromal Tumors
31
Carcinoma, Non-Small-Cell Lung
22
Prostatic Neoplasms
16
Urinary Bladder Neoplasms
13
Colorectal Neoplasms
12
Brain Neoplasms
12
Pancreatic Neoplasms
11
Glioblastoma
11
Carcinoma, Hepatocellular
11
Melanoma
10
Lung Neoplasms
10
Carcinoma
10
Stomach Neoplasms
8
Neuroendocrine Tumors
8
Thyroid Neoplasms
7
Sarcoma
7
Ovarian Neoplasms
7
Multiple Myeloma
7
Liver Neoplasms
7
Adenoma, Islet Cell
7
Small Cell Lung Carcinoma
6
Leukemia, Myeloid, Acute
6
Glioma
6
Esophageal Neoplasms
6
Clear-cell metastatic renal cell carcinoma
6
Interventions
pembrolizumab
3
Pemetrexed
2
Cholecalciferol
2
vorasidenib
1
relacorilant
1
glutathione pegylated liposomal doxorubicin
1
ficlatuzumab
1
bosutinib
1
Trastuzumab
1
Sunitinib
1
Morphine
1
Methadone
1
MRX-2843
1
Letrozole
1
Imatinib Mesylate
1
Electrochemotherapy
1
Control Groups
1
Clomiphene
1
Cisplatin
1
Carboplatin
1
Bleomycin
1
Bevacizumab
1
Azacitidine
1
Aspirin
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Pathologic Processes
×
Sunitinib
×
Clear all
NCT01215565
2014-03-13
Fibrolam
Assistance Publique - Hôpitaux de Paris
Phase 2
Terminated
4 enrolled